Last quarter (Q2 2022), Creo Medical's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, Creo Medical's net income was £―. See Creo Medical’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	£ 27.17M	£ 25.16M	£ 9.43M	£ 13.47K	£ 0.00
Cost of Revenue	-	£ 14.05M	£ 13.58M	£ 5.39M	£ 8.52K	£ 0.00
Gross Profit	-	£ 13.12M	£ 11.59M	£ 4.04M	£ 4.95K	£ 0.00
Operating Expense	-	£ 43.93M	£ 41.49M	£ 27.52M	£ 18.88M	£ 17.66M
Operating Income	-	£ -30.81M	£ -29.91M	£ -23.48M	£ -18.88M	£ -17.66M
Net Non Operating Interest Income Expense	-	£ -253.00K	£ 332.00K	£ 5.00K	£ 287.89K	£ 76.74K
Other Income Expense	-	£ -83.00K	-	-	-	-
Pretax Income	-	£ -30.98M	£ -30.34M	£ -23.46M	£ -18.62M	£ -17.58M
Tax Provision	-	£ -4.04M	£ -5.74M	£ -3.15M	£ -2.70M	£ -2.77M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ -26.94M	£ -24.59M	£ -20.32M	£ -15.91M	£ -14.81M
Basic EPS	-	£ -0.15	£ -0.15	£ -0.13	£ -0.13	£ -0.16
Diluted EPS	-	£ -0.15	£ -0.15	£ -0.13	£ -0.13	£ -0.16
Basic Average Shares	-	£ 181.34M	£ 164.43M	£ 155.93M	£ 121.45M	£ 90.39M
Diluted Average Shares	-	£ 181.34M	£ 164.43M	£ 155.93M	£ 121.45M	£ 90.39M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	£ -0.13	£ -0.16
Reported Normalized Diluted E P S	-	-	-	-	£ -0.13	£ -0.16
Rent Expense Supplemental	-	-	-	-	£ 0.00	£ 333.14K
Total Expenses	-	£ 57.98M	£ -55.07M	£ 32.91M	£ 18.89M	£ 17.66M
Net Income From Continuing And Discontinued Operation	-	£ -26.94M	£ -24.59M	£ -20.32M	£ -15.91M	£ -14.81M
Normalized Income	-	£ -35.02M	£ -36.08M	£ -20.33M	£ -15.89M	£ -14.82M
Interest Expense	-	-	-	£ 173.00K	£ 23.40K	£ 16.74K
EBIT	-	£ -30.77M	£ -29.98M	£ -23.29M	£ -18.59M	£ -17.56M
EBITDA	-	£ -27.66M	£ -29.98M	£ -21.69M	£ -17.95M	£ -17.06M

Currency in GBP

Creo Medical Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing